JPS6161630B2 - - Google Patents

Info

Publication number: JPS6161630B2
Authority: JP; Japan
Prior art keywords: fdp; fragment; fibrinogen; fgdp; blood
Prior art date: 1981-07-16
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired

Application number

JP11130181A

Other languages

English (en)

Japanese (ja)

Other versions

JPS5811856A (ja

Inventor

Juji Inada

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Individual

Original Assignee

Individual

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1981-07-16

Filing date

1981-07-16

Publication date

1986-12-26

1981-07-16 Application filed by Individual filed Critical Individual

1981-07-16 Priority to JP11130181A priority Critical patent/JPS5811856A/ja

1983-01-22 Publication of JPS5811856A publication Critical patent/JPS5811856A/ja

1986-12-26 Publication of JPS6161630B2 publication Critical patent/JPS6161630B2/ja

Status Granted legal-status Critical Current

Links

239000012634 fragment Substances 0.000 claims description 15
108010049003 Fibrinogen Proteins 0.000 claims description 14
102000008946 Fibrinogen Human genes 0.000 claims description 14
229940012952 fibrinogen Drugs 0.000 claims description 14
210000002966 serum Anatomy 0.000 claims description 10
210000004369 blood Anatomy 0.000 claims description 8
239000008280 blood Substances 0.000 claims description 8
239000000539 dimer Substances 0.000 claims description 8
239000000178 monomer Substances 0.000 claims description 6
230000006058 immune tolerance Effects 0.000 claims description 3
238000004519 manufacturing process Methods 0.000 claims description 3
241000124008 Mammalia Species 0.000 claims description 2
241001465754 Metazoa Species 0.000 claims description 2
108010073385 Fibrin Proteins 0.000 description 9
102000009123 Fibrin Human genes 0.000 description 9
BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 9
229950003499 fibrin Drugs 0.000 description 9
239000007857 degradation product Substances 0.000 description 5
238000000034 method Methods 0.000 description 5
230000020764 fibrinolysis Effects 0.000 description 4
208000007536 Thrombosis Diseases 0.000 description 3
239000002671 adjuvant Substances 0.000 description 3
102000015081 Blood Coagulation Factors Human genes 0.000 description 2
108010039209 Blood Coagulation Factors Proteins 0.000 description 2
241000700198 Cavia Species 0.000 description 2
108090000190 Thrombin Proteins 0.000 description 2
230000023555 blood coagulation Effects 0.000 description 2
239000003114 blood coagulation factor Substances 0.000 description 2
230000015556 catabolic process Effects 0.000 description 2
238000006731 degradation reaction Methods 0.000 description 2
208000009190 disseminated intravascular coagulation Diseases 0.000 description 2
239000003527 fibrinolytic agent Substances 0.000 description 2
230000003480 fibrinolytic effect Effects 0.000 description 2
230000023597 hemostasis Effects 0.000 description 2
229940012957 plasmin Drugs 0.000 description 2
238000001556 precipitation Methods 0.000 description 2
238000005303 weighing Methods 0.000 description 2
102000004506 Blood Proteins Human genes 0.000 description 1
108010017384 Blood Proteins Proteins 0.000 description 1
241000282472 Canis lupus familiaris Species 0.000 description 1
241000700199 Cavia porcellus Species 0.000 description 1
241000283086 Equidae Species 0.000 description 1
241000282326 Felis catus Species 0.000 description 1
108010058861 Fibrin Fibrinogen Degradation Products Proteins 0.000 description 1
102000003886 Glycoproteins Human genes 0.000 description 1
108090000288 Glycoproteins Proteins 0.000 description 1
KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
239000004472 Lysine Substances 0.000 description 1
241000283973 Oryctolagus cuniculus Species 0.000 description 1
241001494479 Pecora Species 0.000 description 1
230000005856 abnormality Effects 0.000 description 1
238000004458 analytical method Methods 0.000 description 1
239000003146 anticoagulant agent Substances 0.000 description 1
210000004204 blood vessel Anatomy 0.000 description 1
238000004132 cross linking Methods 0.000 description 1
238000000354 decomposition reaction Methods 0.000 description 1
238000001514 detection method Methods 0.000 description 1
230000002255 enzymatic effect Effects 0.000 description 1
239000000208 fibrin degradation product Substances 0.000 description 1
239000000282 fibrinogen degradation product Substances 0.000 description 1
125000000404 glutamine group Chemical group N[C@@H](CCC(N)=O)C(=O)* 0.000 description 1
229940106780 human fibrinogen Drugs 0.000 description 1
230000001900 immune effect Effects 0.000 description 1
230000000951 immunodiffusion Effects 0.000 description 1
230000006057 immunotolerant effect Effects 0.000 description 1
238000010253 intravenous injection Methods 0.000 description 1
238000012544 monitoring process Methods 0.000 description 1
230000001575 pathological effect Effects 0.000 description 1
230000007170 pathology Effects 0.000 description 1
229920000642 polymer Polymers 0.000 description 1
238000006116 polymerization reaction Methods 0.000 description 1
229920001184 polypeptide Polymers 0.000 description 1
239000002244 precipitate Substances 0.000 description 1
102000004196 processed proteins & peptides Human genes 0.000 description 1
108090000765 processed proteins & peptides Proteins 0.000 description 1
239000000047 product Substances 0.000 description 1
238000011002 quantification Methods 0.000 description 1
238000003127 radioimmunoassay Methods 0.000 description 1
230000000087 stabilizing effect Effects 0.000 description 1
208000011580 syndromic disease Diseases 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
229960004072 thrombin Drugs 0.000 description 1
230000002537 thrombolytic effect Effects 0.000 description 1
125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum

Landscapes

Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Mycology (AREA)
Bioinformatics & Cheminformatics (AREA)
Immunology (AREA)
Microbiology (AREA)
Engineering & Computer Science (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

JP11130181A 1981-07-16 1981-07-16 抗フラグメントＤγ−２量体血清の製造方法 Granted JPS5811856A (ja)

Priority Applications (1)

Application Number	Priority Date	Filing Date	Title
JP11130181A JPS5811856A (ja)	1981-07-16	1981-07-16	抗フラグメントＤγ−２量体血清の製造方法

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
JP11130181A JPS5811856A (ja)	1981-07-16	1981-07-16	抗フラグメントＤγ−２量体血清の製造方法

Publications (2)

Publication Number	Publication Date
JPS5811856A JPS5811856A (ja)	1983-01-22
JPS6161630B2 true JPS6161630B2 (de)	1986-12-26

Family

ID=14557744

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
JP11130181A Granted JPS5811856A (ja)	1981-07-16	1981-07-16	抗フラグメントＤγ−２量体血清の製造方法

Country Status (1)

Country	Link
JP (1)	JPS5811856A (de)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE3400434A1 (de) *	1984-01-09	1985-09-26	Behringwerke Ag, 3550 Marburg	Bestimmung von fibrin mit fibrin-spezifischen antikoerpern
JPS60233553A (ja) *	1984-05-04	1985-11-20	Dai Ichi Pure Chem Co Ltd	フイブリノゲン・フイブリン分解産物の測定方法
JPS60257363A (ja) *	1984-06-05	1985-12-19	Dai Ichi Pure Chem Co Ltd	Ｆｄｐの測定法
JPS60257364A (ja) *	1984-06-05	1985-12-19	Dai Ichi Pure Chem Co Ltd	フイブリノゲン・フイブリン分解産物の測定法

1981
- 1981-07-16 JP JP11130181A patent/JPS5811856A/ja active Granted

Also Published As

Publication number	Publication date
JPS5811856A (ja)	1983-01-22

Similar Documents

Publication	Publication Date	Title
Boneu et al.	1991	D-Dimers, thrombin antithrombin III complexes and prothrombin fragments 1+ 2: diagnostic value in clinically suspected deep vein thrombosis
Coleman et al.	1972	Inhibition of fibrin monomer polymerization by lambda myeloma globulins
Bang et al.	1974	Soluble fibrin complexes
BRPI0711145A2 (pt)	2011-08-23	detecção de doenças venosas tromboembólicas pela medição de nìveis de fibrina solúvel e dìmeros d
Gerrits et al.	1974	Fibrinopeptide A immunoreactivity in human plasma
US6673561B1 (en)	2004-01-06	Diagnostic test for thrombotic or thromboembolic disease
JPH0772200B2 (ja)	1995-08-02	人フィブリンｉｉのｎｈ２末端フラグメントに対するモノクロナール抗体
Connaghan et al.	1985	Specific identification of fibrin polymers, fibrinogen degradation products, and crosslinked fibrin degradation products in plasma and serum with a new sensitive technique
Switalska et al.	1985	A method radioimmunoassay of human platelet thrombospondin: Different patterns of thrombospondin and β-thromboglobulin antigen secretion and clearance from the circulation
JP2918688B2 (ja)	1999-07-12	プロトロンビン活性化ペプチド及びその分解産物に関するイムノアッセイ及びそれらに対するモノクローナル抗体
Dempfle et al.	1995	Comparison of immunological and functional assays for measurement of soluble fibrin
US4216291A (en)	1980-08-05	Thrombosis-test
Mejía et al.	2014	Endogenous thrombin potential in Behçet’s disease: relationship with thrombosis and anticoagulant therapy
Roussi et al.	1999	Contribution of D-Dimer determination in the exclusion of deep venous thrombosis in spinal cord injury patients
Sié et al.	1994	D-dimer levels in patients with long-term antecedents of deep venous thrombosis
Ueyama et al.	1989	Progressing ischemic stroke in a homozygote with variant antithrombin III.
Molinas et al.	1981	Factor VIII: C and factor VIII R: Ag in Argentine hemorrhagic fever
JPS5811856A (ja)	1983-01-22	抗フラグメントＤγ−２量体血清の製造方法
Reber et al.	1999	Performances of the fibrin monomer test for the exclusion of pulmonary embolism in symptomatic outpatients
Verhaeghe et al.	1974	Fibrinogen ‘Leuven’, another genetic variant
Chang et al.	1974	Soluble fibrin complexes in experimental thrombotic states
AU781249B2 (en)	2005-05-12	Diagnostic test for thrombotic or thromboembolic disease
Hansen et al.	1975	Enhancement of blood coagulation by soluble fibrin complexes.
Merlini et al.	1995	Laboratory measurement of thrombin activity—What every clinician scientist needs to know
Arkin et al.	1979	The hypercoagulability states